Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer

Petteri Hervonen, Heikki Joensuu, Timo Joensuu, Claes Ginman, Ray McDermott, Ulrika Harmenberg, Paul Nyandoto, Tiina Luukkaala, Akseli Hemminki, Igor Zaitsev, Mirja Heikkinen, Sten Nilsson, Marjaana Luukkaa, Ilari Lehtinen, Pirkko-Liisa Kellokumpu-Lehtinen

    Research output: Contribution to journalArticleScientificpeer-review

    22 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)953-956
    JournalAnticancer Research
    Volume32
    Issue number3
    Publication statusPublished - 2012
    Publication typeA1 Journal article-refereed

    Keywords

    • chemotherapy
    • docetaxel
    • prostate cancer

    Publication forum classification

    • Publication forum level 1

    Cite this